MicroRNA-155 Protects Group 2 Innate Lymphoid Cells From Apoptosis to Promote Type-2 Immunity

por Knolle, Martin D., Chin, Shau Bing, Rana, Batika M. J., Englezakis, Alexandros, Nakagawa, Rinako, Fallon, Padraic G., Git, Anna, McKenzie, Andrew N. J.
Publicado 2018

Combining clinical, radiological and genetic approaches to pneumothorax management

por Grimes, Hannah L, Holden, Simon, Babar, Judith, Karia, Sumit, Wetscherek, Maria TA, Barker, Allanah, Herre, Jurgen, Knolle, Martin D, Maher, Eamonn R, Marciniak, Stefan John
Publicado 2022

An αvβ3 integrin checkpoint is critical for efficient T(H)2 cytokine polarisation and potentiating antigen-specific immunity

por Szeto, Aydan C. H., Ferreira, Ana C. F., Mannion, Jonathan, Clark, Paula A., Sivasubramaniam, Meera, Heycock, Morgan W. D., Crisp, Alastair, Jolin, Helen E., Kozik, Patrycja, Knolle, Martin D., McKenzie, Andrew N. J.
Publicado 2023

Tissue-Restricted Adaptive Type 2 Immunity Is Orchestrated by Expression of the Costimulatory Molecule OX40L on Group 2 Innate Lymphoid Cells

por Halim, Timotheus Y.F., Rana, Batika M.J., Walker, Jennifer A., Kerscher, Bernhard, Knolle, Martin D., Jolin, Helen E., Serrao, Eva M., Haim-Vilmovsky, Liora, Teichmann, Sarah A., Rodewald, Hans-Reimer, Botto, Marina, Vyse, Timothy J., Fallon, Padraic G., Li, Zhi, Withers, David R., McKenzie, Andrew N.J.
Publicado 2018

How achievable are COVID-19 clinical trial recruitment targets? A UK observational cohort study and trials registry analysis

por Cunniffe, Nick G, Gunter, Simon J, Brown, Michael, Burge, Sarah W, Coyle, Clare, De Soyza, Anthony, Dymond, Tom, Esmail, Hanif, Francis, Darrel P, Galloway, Jacqui, Galloway, James B, Gkrania-Klotsas, Effrossyni, Greenaway, Jane, Katritsis, George, Kanagaratnam, Prapa, Knolle, Martin D, Leonard, Kelly, McIntyre, Zoe C, Prudon, Ben, Rampling, Tommy, Torok, Mili Estee, Warne, Ben, Yates, Mark, Matheson, Nicholas J, Su, Li, Villar, Sofia, Stewart, Grant D, Toshner, Mark
Publicado 2020